Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Meta Expands AI Training With Employee Activity Tracking Tools 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
HOUSTON, March 10, 2017 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2017 American Association for Cancer Research (AACR) Annual Meeting, taking place from April 1-5, 2017 in Washington D.C. Dr. Ana Tari Ashizawa, Director of Research at Bio-Path, will present preclinical data of BP1002 (Liposomal Bcl2 antisense), the Company’s second drug candidate, for the treatment of aggressive non-Hodgkin's lymphoma.
Details for the poster presentation are as follows:
Date: Wednesday, April 5, 2017
Presentation Time: 8:00 am – 12:00 pm Eastern Time
Location: Walter E. Washington Convention Center
Session: Gene and Vector Based Therapy, Section 3
Abstract: 5091
Title: “Activity of Bcl-2 antisense therapeutic in aggressive non-Hodgkin's lymphoma” (Link to abstract)
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information: Investors Will O’Connor Stern Investor Relations, Inc. 212-362-1200 [email protected] Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
